Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Are there differential sy… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?

Artikel i vetenskaplig tidskrift
Författare Uriel Halbreich
P M Shaughn O'Brien
Elias Eriksson
Torbjörn Bäckström
Kimberly A Yonkers
Ellen W Freeman
Publicerad i CNS drugs
Volym 20
Nummer/häfte 7
Sidor 523-47
ISSN 1172-7047
Publiceringsår 2006
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi
Sidor 523-47
Språk en
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Central Nervous System, drug effects, physiopathology, Drug Therapy, Combination, Estrogen Antagonists, therapeutic use, Female, Gonadotropin-Releasing Hormone, agonists, Humans, MEDLINE, statistics & numerical data, Meta-Analysis, Ovariectomy, methods, Premenstrual Syndrome, classification, drug therapy, physiopathology, surgery, Randomized Controlled Trials, Serotonin Uptake Inhibitors, therapeutic use
Ämneskategorier Fysiologi

Sammanfattning

Current evidence suggests that the accepted treatments for premenstrual syndrome (PMS)/premenstrual dysphoric disorder (PMDD) have similar overall efficacy. While these treatments are more effective than placebo, response rates associated with them are far from satisfactory (<60%), such that, irrespective of treatment modality, there remain a significant number of women who are unresponsive to current conventional pharmacological therapy. The available data on response rates of specific types of premenstrual symptoms to, or symptom profiles that are most amenable to, each treatment modality are limited and not well defined because most studies were not designed to assess specific symptom profiles. Those studies that have attempted to evaluate which symptom profiles respond to specific therapies have revealed variations within the individual modalities, as well as between the different modalities. It appears that suppression of ovulation ameliorates a broad range of behavioural as well as physical premenstrual symptoms. SSRIs are most effective for irritability and anxiety symptoms, with lesser efficacy for 'atypical' premenstrual symptoms. GABAergic compounds are most efficacious for anxiety and anxious/depressive symptoms, while dopamine agonists, particularly bromocriptine, are perhaps most efficacious for mastalgia. Overall treatment response rates may improve if treatments are targeted at well-defined subgroups of patients. Re-analysis of available datasets from randomised clinical trials may shed more light on the notion that targeting women with specific premenstrual symptom profiles for specific treatment modalities would improve response rates beyond the current ceiling of approximately 60%. Such information would also improve understanding of the putative pathophysiological mechanisms underlying PMS and PMDD, and may point to a more specific diagnosis of these conditions.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?